Stocks
Blueprint Medicines Corporation Financial Statements (BPMC) |
||||||||||
| Blueprint Medicines Corporationsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 13.02.2020 | 17.02.2021 | 17.02.2022 | 16.02.2023 | 15.02.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 66.5 | 793.7 | 180.1 | 204.0 | 249.4 | 282.2 | |||
| Operating Income, bln rub | -366.6 | 302.1 | -648.5 | -549.3 | -486.3 | -440.9 | ||||
| EBITDA, bln rub | ? | -361.3 | 308.7 | -642.0 | -537.5 | -474.6 | -434.6 | |||
| Net profit, bln rub | ? | -328.7 | 313.9 | -644.1 | -557.5 | -507.0 | -288.3 | |||
| OCF, bln rub | ? | -278.0 | 387.0 | -298.7 | -502.3 | -436.8 | -415.4 | |||
| CAPEX, bln rub | ? | 14.0 | 3.16 | 261.2 | 8.92 | 16.1 | 14.6 | |||
| FCF, bln rub | ? | -292.0 | 383.9 | -559.9 | -511.2 | -452.9 | -430.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 427.8 | 484.6 | 804.1 | 723.7 | 711.2 | 706.4 | ||||
| Cost of production, bln rub | 0.000 | 0.425 | 17.9 | 17.8 | 24.5 | 16.7 | ||||
| R&D, bln rub | 331.5 | 326.9 | 601.0 | 477.4 | 416.1 | 399.7 | ||||
| Interest expenses, bln rub | 13.7 | 0.000 | 0.000 | 16.8 | 51.6 | 37.9 | ||||
| Assets, bln rub | 707.7 | 1 718 | 1 252 | 1 350 | 1 049 | 1 038 | ||||
| Net Assets, bln rub | ? | 464.4 | 1 470 | 970.7 | 514.7 | 130.6 | 310.7 | |||
| Debt, bln rub | 95.9 | 89.6 | 111.4 | 242.5 | 774.1 | 597.9 | ||||
| Cash, bln rub | 548.0 | 1 550 | 1 035 | 1 078 | 710.6 | 647.9 | ||||
| Net debt, bln rub | -452.0 | -1 460 | -923.2 | -836.0 | 63.5 | -50.0 | ||||
| Ordinary share price, rub | 80.1 | 112.2 | 107.1 | 43.8 | 92.2 | 59.5 | ||||
| Number of ordinary shares, mln | 47.8 | 54.5 | 58.5 | 59.6 | 60.6 | 61.6 | ||||
| Market cap, bln rub | 3 832 | 6 116 | 6 268 | 2 613 | 5 586 | 3 662 | ||||
| EV, bln rub | ? | 3 380 | 4 656 | 5 345 | 1 777 | 5 649 | 3 612 | |||
| Book value, bln rub | 464 | 1 470 | 971 | 515 | 131 | 311 | ||||
| EPS, rub | ? | -6.87 | 5.76 | -11.0 | -9.35 | -8.37 | -4.68 | |||
| FCF/share, rub | -6.11 | 7.04 | -9.57 | -8.57 | -7.48 | -6.98 | ||||
| BV/share, rub | 9.71 | 27.0 | 16.6 | 8.63 | 2.16 | 5.05 | ||||
| EBITDA margin, % | ? | -543.2% | 38.9% | -356.5% | -263.4% | -190.3% | -154.0% | |||
| Net margin, % | ? | -494.2% | 39.5% | -357.7% | -273.2% | -203.3% | -102.2% | |||
| FCF yield, % | ? | -7.62% | 6.28% | -8.93% | -19.6% | -8.11% | -11.7% | |||
| ROE, % | ? | -70.8% | 21.4% | -66.4% | -108.3% | -388.2% | -92.8% | |||
| ROA, % | ? | -46.4% | 18.3% | -51.4% | -41.3% | -48.3% | -27.8% | |||
| P/E | ? | -11.7 | 19.5 | -9.73 | -4.69 | -11.0 | -12.7 | |||
| P/FCF | -13.1 | 15.9 | -11.2 | -5.11 | -12.3 | -8.52 | ||||
| P/S | ? | 57.6 | 7.71 | 34.8 | 12.8 | 22.4 | 13.0 | |||
| P/BV | ? | 8.25 | 4.16 | 6.46 | 5.08 | 42.8 | 11.8 | |||
| EV/EBITDA | ? | -9.35 | 15.1 | -8.33 | -3.31 | -11.9 | -8.31 | |||
| Debt/EBITDA | 1.25 | -4.73 | 1.44 | 1.56 | -0.13 | 0.11 | ||||
| R&D/CAPEX, % | 2 365% | 10 347% | 230.1% | 5 353% | 2 590% | 2 741% | ||||
| CAPEX/Revenue, % | 21.1% | 0.40% | 145.1% | 4.37% | 6.44% | 5.17% | ||||
| Blueprint Medicines Corporation shareholders | ||||||||||
